Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Pharmaciana: Jurnal Kefarmasian Science Midwifery
Bintang, Muhamad Ilham
Unknown Affiliation
Dentistry Health Professions Medicine & Pharmacology Nursing Public Health Veterinary

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
In silico study of Sambiloto (Andrographis paniculata) compounds from GC-MS and LC-MS/MS as alpha-glucosidase and DPP-4 enzyme inhibitor Kusriani, Herni; Purwaniati, Purwaniati; Bintang, Muhamad Ilham
Pharmaciana Vol. 14 No. 3 (2024): Pharmaciana
Publisher : Universitas Ahmad Dahlan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.12928/pharmaciana.v14i3.26643

Abstract

Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia, impaired insulin secretion, and insulin action. To overcome this disease, some people treat it with natural ingredients. Sambiloto (Andrographis paniculata) is reported to have a wide range of pharmacological activities, one of which is anti-diabetic. Sambiloto showed activity in lowering blood glucose which has the potential as an antidiabetic. Computational methods, such as molecular docking, can increase the effectiveness and reduce the cost of searching for new active compounds. The purpose of this study was to determine the component compounds contained in the ethanol extract of Sambiloto and obtain the potential compounds to inhibit the alpha-glucosidase and DPP-4 enzymes as anti-diabetics with molecular docking method. Sambiloto leaves were macerated for 3 x 24 hours using ethanol 96% as a solvent and concentrated with an evaporator. Sambiloto extract was analyzed using LC-MS, and GC-MS. In-silico analysis includes geometry optimization and molecular docking methods. Preparation of the test ligands was carried out by the ChemBioDraw Ultra and ChemBio3D applications, then optimization by Gaussian 09 application. The crystal structures of the target proteins used were those with PDB ID 5NN8 for alpha-glucosidase and 2QOE for DPP-4. Molecular docking was performed using Autodock 4.2.3 application. From analysis with LC- MS/MS and GC-MS methods, 18 compounds were identified. Molecular docking was performed on the identified compounds. The results of molecular docking showed that the compound S17 (11-(P- Bromoanilino)-5H-Dibenzo [B,E] [1,4] Diazepine), S1 (andrographolide) and S2 (andrographanin) have the potential to inhibit the activity of alpha-glucosidase enzyme; on the other hand S17 (11-(P-Bromoanilino)-5H-Dibenzo [B,E][1,4]Diazepine) and S5 (andrographolactone) have the potential to inhibit the activity of DPP-4 enzyme. These compounds have the potential to inhibit alpha- glucosidase and DPP-4 enzymes which act as antidiabetics.
Review: RNA therapy for type 1 & 2 diabetes Bintang, Muhamad Ilham; Asnawi, Aiyi; Agita, Widhiya
Science Midwifery Vol 12 No 2 (2024): June: Health Sciences and related fields
Publisher : Institute of Computer Science (IOCS)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35335/midwifery.v12i2.1594

Abstract

Diabetes is a group of metabolic disorders with high blood glucose levels. In type 1 diabetes, blood glucose increases due to damage to pancreatic beta cells. In type 2 diabetes, insulin production is ineffective in glucose uptake into target tissues, increasing glucose levels. Advances in RNA-based technologies indicate that RNA molecules have multiple roles in disease initiation and progression. This review discusses recent developments in RNA therapy for type 1 and type 2 diabetes. RNA therapies, such as mRNA, miRNA, siRNA, lncRNA, and circRNA, show great potential. mRNA and miRNA are important in pancreatic cell development, insulin resistance, insulin sensitivity, and insulin secretion. siRNA improves glucose regulation and improves beta cell dysfunction in T1D and T2D. lncRNAs regulate beta cell responses to inflammation and insulin resistance. circRNA plays a role in M1 macrophage activation associated with T1D pathogenesis and regulation of insulin transcription and secretion. RNA therapy offers revolutionary possibilities in the management and potential cure of type 1 and type 2 diabetes. It is believed to improve and change the clinical approach to diabetes, with research continuing to develop therapies that are safe, effective, and able to change the paradigm of diabetes treatment.
Co-Authors Agita, Widhiya Aiyi Asnawi Purwaniati, Purwaniati -